Rapamycin decreases airway remodeling and hyperreactivity in a transgenic model of noninflammatory lung disease
- 1 December 2011
- journal article
- research article
- Published by American Physiological Society in Journal of Applied Physiology
- Vol. 111 (6) , 1760-1767
Abstract
Airway hyperreactivity (AHR) and remodeling are cardinal features of asthma and chronic obstructive pulmonary disease. New therapeutic targets are needed as some patients are refractory to current therapies and develop progressive airway remodeling and worsening AHR. The mammalian target of rapamycin (mTOR) is a key regulator of cellular proliferation and survival. Treatment with the mTOR inhibitor rapamycin inhibits inflammation and AHR in allergic asthma models, but it is unclear if rapamycin can directly inhibit airway remodeling and AHR, or whether its therapeutic effects are entirely mediated through immunosuppression. To address this question, we utilized transforming growth factor-α (TGF-α) transgenic mice null for the transcription factor early growth response-1 (Egr-1) (TGF-α Tg/Egr-1ko/ko mice). These mice develop airway smooth muscle thickening and AHR in the absence of altered lung inflammation, as previously reported. In this study, TGF-α Tg/Egr-1ko/ko mice lost body weight and developed severe AHR after 3 wk of lung-specific TGF-α induction. Rapamycin treatment prevented body weight loss, airway wall thickening, abnormal lung mechanics, and increases in airway resistance to methacholine after 3 wk of TGF-α induction. Increases in tissue damping and airway elastance were also attenuated in transgenic mice treated with rapamycin. TGF-α/Egr-1ko/ko mice on doxycycline for 8 wk developed severe airway remodeling. Immunostaining for α-smooth muscle actin and morphometric analysis showed that rapamycin treatment prevented airway smooth muscle thickening around small airways. Pentachrome staining, assessments of lung collagen and fibronectin mRNA levels, indicated that rapamycin also attenuated fibrotic pathways induced by TGF-α expression for 8 wk. Thus rapamycin reduced airway remodeling and AHR, demonstrating an important role for mTOR signaling in TGF-α-induced/EGF receptor-mediated reactive airway disease.Keywords
This publication has 53 references indexed in Scilit:
- Efficacy and Safety of Sirolimus in LymphangioleiomyomatosisNew England Journal of Medicine, 2011
- mTOR is required for pulmonary arterial vascular smooth muscle cell proliferation under chronic hypoxiaThe FASEB Journal, 2011
- Epithelial EGF receptor signaling mediates airway hyperreactivity and remodeling in a mouse model of chronic asthmaAmerican Journal of Physiology-Lung Cellular and Molecular Physiology, 2011
- Activating mutations of TOR (target of rapamycin)Genes to Cells, 2011
- The Mammalian Target of Rapamycin: Linking T Cell Differentiation, Function, and MetabolismImmunity, 2010
- Rapamycin fed late in life extends lifespan in genetically heterogeneous miceNature, 2009
- Conditional Expression of Genes in the Respiratory Epithelium in Transgenic MiceAmerican Journal of Respiratory Cell and Molecular Biology, 2009
- The Synergistic Interactions of Allergic Lung Inflammation and Intratracheal Cationic ProteinAmerican Journal of Respiratory and Critical Care Medicine, 2008
- Genomic Profile of Matrix and Vasculature Remodeling in TGF-α–Induced Pulmonary FibrosisAmerican Journal of Respiratory Cell and Molecular Biology, 2007
- Molecular Pathogenesis of LymphangioleiomyomatosisAmerican Journal of Respiratory Cell and Molecular Biology, 2007